Employers and employees spent more than $400 billion on obesity care in 2023; Novo Nordisk’s CEO said weight loss drug Wegovy can reduce these costs — an inverse of critics’ expectations.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
